Scarica l'app Stockscreener
105.98
0.02%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$105.98
Aprire:
$107.38
Volume 24 ore:
2.03M
Relative Volume:
1.00
Capitalizzazione di mercato:
$20.69B
Reddito:
$4.58B
Utile/perdita netta:
$870.87M
Rapporto P/E:
24.09
EPS:
4.3988
Flusso di cassa netto:
$945.58M
1 W Prestazione:
+4.36%
1M Prestazione:
+26.49%
6M Prestazione:
+79.72%
1 anno Prestazione:
+27.13%
Intervallo 1D:
$104.06
$108.81
Intervallo di 1 settimana:
$100.02
$108.81
Portata 52W:
$53.56
$108.81
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
105.97 | 20.81B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.20 | 103.89B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.74 | 69.11B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.70 | 58.49B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
869.83 | 52.62B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
191.92 | 40.46B | 447.02M | -1.18B | -906.14M | -6.1812 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte at Guggenheim Conference: Strategic Focus on Innovation - Investing.com
Published on: 2025-11-10 05:29:16 - newser.com
Forecasting Incyte Corporation price range with options data2025 Analyst Calls & AI Enhanced Trade Execution Alerts - newser.com
Can Incyte Corporation stock deliver sustainable ROEMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Incyte Posts 20% Revenue Growth, Raises 2025 Outlook on Strong Drug Demand - MyChesCo
Incyte and Enable Injections Join Forces to Advance At-Home Cancer Treatments - MyChesCo
Incyte to Highlight Innovation at Major Global Healthcare Conferences in November - MyChesCo
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Incyte Corporation stock outperform Dow Jones indexBull Run & Weekly High Momentum Picks - newser.com
How Incyte Corporation stock responds to policy changesWeekly Trend Report & Smart Money Movement Alerts - newser.com
Key metrics from Incyte Corporation’s quarterly dataWeekly Risk Report & AI Powered Trade Plan Recommendations - newser.com
Incyte EVP Denton sells $60,613 in stock By Investing.com - Investing.com Nigeria
Incyte EVP Denton sells $60,613 in stock - Investing.com
Will Incyte Corporation (ICY) stock return to pre crash levels2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema - The Joplin Globe
Leading vs lagging indicators on Incyte Corporation performanceJuly 2025 Summary & Real-Time Volume Triggers - newser.com
Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
Can Incyte Corporation (ICY) stock attract analyst upgradesShort Setup & Smart Money Movement Alerts - newser.com
Incyte (NASDAQ:INCY) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Incyte stock hits 52-week high at 103.93 USD - Investing.com
Will Incyte Corporation stock see PE expansionWatch List & Technical Buy Zone Confirmation - newser.com
Incyte Unveils Game-Changing mCALR Trials – What It Means for Blood Cancer Treatment! - Smartkarma
Incyte (INCY) Secures $935M Deal with Prelude Therapeutics for J - GuruFocus
Incyte secures option to acquire Prelude’s JAK2V617F inhibitor program By Investing.com - Investing.com South Africa
Incyte (INCY) Receives Raised Price Target from Piper Sandler | - GuruFocus
Incyte (NASDAQ:INCY) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Incyte aboard, SMARCA2 shift by Prelude enshrouds Foghorn - BioWorld MedTech
Prelude Therapeutics Signs Option Agreement with Incyte - TipRanks
Incyte (NASDAQ:INCY) Upgraded by Guggenheim to Buy Rating - MarketBeat
Incyte (INCY) Secures Option for JAK2V617F Program in $910M Deal - GuruFocus
Incyte secures option to acquire Prelude’s JAK2V617F inhibitor program - Investing.com
Incyte (INCY) Secures Exclusive Option on JAK2V617F Program - GuruFocus
Prelude Therapeutics stock climbs after exclusive JAK2 option deal with Incyte - Investing.com
Prelude Therapeutics Announces Strategic Updates: Prioritizes JAK2V617F and KAT6A Programs, Pauses SMARCA2 Development and Secures $60 Million from Incyte Option Agreement - Quiver Quantitative
Hussman Strategic Advisors Inc. Boosts Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage - Insider Monkey
The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call - Barchart.com
Incyte Corporation (INCY) Stock Forecasts - Yahoo! Finance Canada
Incyte Corporation (INCY) Stock forecasts - Yahoo! Finance UK
Is Incyte Corporation (ICY) stock dividend growth reliableJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Incyte Corp. Stock Climbs 8.7%, Outperforms Peers - 富途牛牛
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte (INCY) Upgraded to Buy by Guggenheim, Price Target Set at $125 | INCY Stock News - GuruFocus
Incyte stock jumps on promising cancer data - Investing.com
Is It Too Late to Ride INCY’s Upsurge? - timothysykes.com
Is Incyte Soaring or Sinking? - StocksToTrade
Incyte (INCY) Shares Rise Following Promising Myelofibrosis Data - GuruFocus
INCY: Promising Myelofibrosis Treatment Bolsters Incyte's Prospe - GuruFocus
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting - Yahoo Finance
Is Incyte Corporation building a consolidation basePortfolio Value Report & AI Enhanced Trading Alerts - newser.com
What’s next for Incyte Corporation stock priceEarnings Overview Summary & Weekly Breakout Stock Alerts - newser.com
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Incyte Corp Azioni (INCY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Stein Steven H | EVP & Chief Medical Officer |
Nov 05 '25 |
Sale |
102.20 |
5,233 |
534,813 |
102,886 |
| Denton Sheila A. | EVP & General Counsel |
Nov 04 '25 |
Option Exercise |
58.06 |
598 |
34,720 |
27,167 |
| Denton Sheila A. | EVP & General Counsel |
Nov 04 '25 |
Sale |
101.36 |
598 |
60,613 |
26,569 |
1.41%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):